BIOMAT Database Logo BIOMAT Database Logo

Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. 2001

S M Palmer, and R H Drew, and J D Whitehouse, and V F Tapson, and R D Davis, and R R McConnell, and S S Kanj, and J R Perfect
Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, NC 22710, USA.

BACKGROUND Fungal infections remain an important cause of morbidity and mortality in lung transplant recipients. Aerosolized amphotericin B lipid complex (ABLC) may be more efficacious than conventional amphotericin B in the prevention of fungal infections in animal models, but experience with aerosolized ABLC in humans is lacking. METHODS We conducted a prospective, noncomparative study designed to evaluate safety of aerosolized ABLC in lung or heart-lung transplant recipients. RESULTS A total of 381 treatments were administered to 51 patients. Complete spirometry records were available for 335 treatments (69 in intubated patients, 266 in extubated patients). ABLC was subjectively well tolerated in 98% of patients. Pulmonary mechanics worsened by 20% or more posttreatment in less than 5% of all treatments. There were no significant adverse events related to study medication in any patient, and 1-year survival for all enrolled patients was 78%. CONCLUSIONS Administration of nebulized ABLC is safe in the short-term and well-tolerated in lung transplant recipients. Additional prospective, randomized studies are needed to determine the efficacy of aerosolized ABLC alone or in conjunction with systemic therapies in the prevention of fungal infections in lung transplant recipients.

UI MeSH Term Description Entries
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009181 Mycoses Diseases caused by FUNGI. Fungus Diseases,Fungal Diseases,Fungal Infections,Fungus Infections,Disease, Fungal,Disease, Fungus,Diseases, Fungal,Diseases, Fungus,Fungal Disease,Fungal Infection,Fungus Disease,Fungus Infection,Infection, Fungal,Infection, Fungus,Infections, Fungal,Infections, Fungus
D010538 Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs. Primary Peritonitis,Secondary Peritonitis,Peritonitis, Primary,Peritonitis, Secondary
D010713 Phosphatidylcholines Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety. Choline Phosphoglycerides,Choline Glycerophospholipids,Phosphatidyl Choline,Phosphatidyl Cholines,Phosphatidylcholine,Choline, Phosphatidyl,Cholines, Phosphatidyl,Glycerophospholipids, Choline,Phosphoglycerides, Choline
D010715 Phosphatidylglycerols A nitrogen-free class of lipids present in animal and particularly plant tissues and composed of one mole of glycerol and 1 or 2 moles of phosphatidic acid. Members of this group differ from one another in the nature of the fatty acids released on hydrolysis. Glycerol Phosphoglycerides,Monophosphatidylglycerols,Phosphatidylglycerol,Phosphatidyl Glycerol,Glycerol, Phosphatidyl,Phosphoglycerides, Glycerol
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002177 Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) Candida Infection,Moniliasis,Candida Infections,Candidiases,Infection, Candida,Moniliases
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug

Related Publications

S M Palmer, and R H Drew, and J D Whitehouse, and V F Tapson, and R D Davis, and R R McConnell, and S S Kanj, and J R Perfect
Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients.
December 2010, Transplantation,
S M Palmer, and R H Drew, and J D Whitehouse, and V F Tapson, and R D Davis, and R R McConnell, and S S Kanj, and J R Perfect
Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients.
June 2022, Antimicrobial agents and chemotherapy,
S M Palmer, and R H Drew, and J D Whitehouse, and V F Tapson, and R D Davis, and R R McConnell, and S S Kanj, and J R Perfect
Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients.
November 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
S M Palmer, and R H Drew, and J D Whitehouse, and V F Tapson, and R D Davis, and R R McConnell, and S S Kanj, and J R Perfect
Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients.
October 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
S M Palmer, and R H Drew, and J D Whitehouse, and V F Tapson, and R D Davis, and R R McConnell, and S S Kanj, and J R Perfect
Amphotericin B in lung transplant recipients.
January 2002, The Annals of pharmacotherapy,
S M Palmer, and R H Drew, and J D Whitehouse, and V F Tapson, and R D Davis, and R R McConnell, and S S Kanj, and J R Perfect
Safety of aerosolized amphotericin B.
September 2007, Expert opinion on drug safety,
S M Palmer, and R H Drew, and J D Whitehouse, and V F Tapson, and R D Davis, and R R McConnell, and S S Kanj, and J R Perfect
Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections.
August 2000, Clinical transplantation,
S M Palmer, and R H Drew, and J D Whitehouse, and V F Tapson, and R D Davis, and R R McConnell, and S S Kanj, and J R Perfect
Safety of high-dose amphotericin B lipid complex.
July 1999, Bone marrow transplantation,
S M Palmer, and R H Drew, and J D Whitehouse, and V F Tapson, and R D Davis, and R R McConnell, and S S Kanj, and J R Perfect
Amphotericin B disposition after aerosol inhalation in lung transplant recipients.
January 2002, The Annals of pharmacotherapy,
S M Palmer, and R H Drew, and J D Whitehouse, and V F Tapson, and R D Davis, and R R McConnell, and S S Kanj, and J R Perfect
Aerosolized amphotericin B lipid complex and invasive pulmonary aspergillosis: a case report.
March 2015, Le infezioni in medicina,
Copied contents to your clipboard!